Maia Kayal1, Alexa Riggs2, Michael Plietz3, Sergey Khaitov3, Patricia Sylla3, Alexander J Greenstein3, Noam Harpaz4, Steven H Itzkowitz2, Shailja C Shah5. 1. Department of Medicine, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1069, New York, NY, USA. Maia.Kayal@mountsinai.org. 2. Department of Medicine, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1069, New York, NY, USA. 3. Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Department of Medicine, Division of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
BACKGROUND: The risk of neoplasia of the pouch or residual rectum in patients with ulcerative colitis (UC) who undergo total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is incompletely investigated. Thiopurine use is associated with a reduced risk of colorectal neoplasia in patients with UC. We tested the hypothesis that thiopurine use prior to TPC may be associated with a reduced risk of primary neoplasia after IPAA. METHODS: We conducted a retrospective cohort analysis of patients from a tertiary referral center from January 2008 to December 2017. Eligible patients with UC or IC underwent TPC with IPAA and had at least two pouchoscopies with biopsies ≥ 6 months after surgery. Propensity score analysis was conducted to match thiopurine exposed vs unexposed groups based on clinical covariates. Multivariable Cox regression analysis estimated the risk of neoplasia. RESULTS: A total of 284 patients with UC or IC (57.4% male, median age 35.6 years) were analyzed. Ninety-seven patients (34.2%) were confirmed to have thiopurine exposure ≥ 12 weeks immediately prior to TPC ("exposed") and 187 (65.8%) were confirmed to have no thiopurine exposure for at least 365 days prior to TPC ("non-exposed"). Compared to non-exposed patients, patients with thiopurine exposure less often had dysplasia (7.2% vs 23.0%, p = 0.001) and had lower grades of dysplasia before colectomy. After IPAA, patients with neoplasia were older (44.0 vs 34.8 years, p = 0.03), more likely to have had dysplasia as colectomy indication (44.4% vs 15.4%, p = 0.007), and more likely to require pouch excision (55.6% vs 10.2%, p < 0.0001), compared to patients without neoplasia. On propensity-matched cohort analysis, no factors were significantly associated with risk of primary neoplasia. CONCLUSION: Thiopurine exposure for at least the 12 weeks prior to TPC in patients with UC or IC does not appear to be independently associated with risk of primary neoplasia following IPAA.
BACKGROUND: The risk of neoplasia of the pouch or residual rectum in patients with ulcerative colitis (UC) who undergo total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is incompletely investigated. Thiopurine use is associated with a reduced risk of colorectal neoplasia in patients with UC. We tested the hypothesis that thiopurine use prior to TPC may be associated with a reduced risk of primary neoplasia after IPAA. METHODS: We conducted a retrospective cohort analysis of patients from a tertiary referral center from January 2008 to December 2017. Eligible patients with UC or IC underwent TPC with IPAA and had at least two pouchoscopies with biopsies ≥ 6 months after surgery. Propensity score analysis was conducted to match thiopurine exposed vs unexposed groups based on clinical covariates. Multivariable Cox regression analysis estimated the risk of neoplasia. RESULTS: A total of 284 patients with UC or IC (57.4% male, median age 35.6 years) were analyzed. Ninety-seven patients (34.2%) were confirmed to have thiopurine exposure ≥ 12 weeks immediately prior to TPC ("exposed") and 187 (65.8%) were confirmed to have no thiopurine exposure for at least 365 days prior to TPC ("non-exposed"). Compared to non-exposed patients, patients with thiopurine exposure less often had dysplasia (7.2% vs 23.0%, p = 0.001) and had lower grades of dysplasia before colectomy. After IPAA, patients with neoplasia were older (44.0 vs 34.8 years, p = 0.03), more likely to have had dysplasia as colectomy indication (44.4% vs 15.4%, p = 0.007), and more likely to require pouch excision (55.6% vs 10.2%, p < 0.0001), compared to patients without neoplasia. On propensity-matched cohort analysis, no factors were significantly associated with risk of primary neoplasia. CONCLUSION: Thiopurine exposure for at least the 12 weeks prior to TPC in patients with UC or IC does not appear to be independently associated with risk of primary neoplasia following IPAA.
Authors: Fiona D M van Schaik; Martijn G H van Oijen; Hugo M Smeets; Geert J M G van der Heijden; Peter D Siersema; Bas Oldenburg Journal: Gut Date: 2011-05-20 Impact factor: 23.059
Authors: Rishi M Goel; Paul Blaker; Alex Mentzer; Steven C M Fong; Anthony M Marinaki; Jeremy D Sanderson Journal: Ther Adv Chronic Dis Date: 2015-05 Impact factor: 5.091
Authors: A L Lightner; P Vaidya; S Vogler; J McMichael; X Jia; M Regueiro; T Qazi; S R Steele; J Church Journal: Br J Surg Date: 2020-07-20 Impact factor: 6.939
Authors: Remi Mahmoud; Shailja C Shah; Joana Torres; Daniel Castaneda; Jason Glass; Jordan Elman; Akash Kumar; Jordan Axelrad; Noam Harpaz; Thomas Ullman; Jean-Frédéric Colombel; Bas Oldenburg; Steven H Itzkowitz Journal: Clin Gastroenterol Hepatol Date: 2019-08-22 Impact factor: 11.382
Authors: Fernando Magro; Paolo Gionchetti; Rami Eliakim; Sandro Ardizzone; Alessandro Armuzzi; Manuel Barreiro-de Acosta; Johan Burisch; Krisztina B Gecse; Ailsa L Hart; Pieter Hindryckx; Cord Langner; Jimmy K Limdi; Gianluca Pellino; Edyta Zagórowicz; Tim Raine; Marcus Harbord; Florian Rieder Journal: J Crohns Colitis Date: 2017-06-01 Impact factor: 10.020